TY - JOUR
T1 - A Roadmap for Integrating Neuroscience into Addiction Treatment
T2 - A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine
AU - Verdejo-Garcia, Antonio
AU - Lorenzetti, Valentina
AU - Manning, Victoria
AU - Piercy, Hugh
AU - Bruno, Raimondo
AU - Hester, Rob
AU - Pennington, David
AU - Tolomeo, Serenella
AU - Arunogiri, Shalini
AU - Bates, Marsha E.
AU - Bowden-Jones, Henrietta
AU - Campanella, Salvatore
AU - Daughters, Stacey
AU - Kouimtsidis, Christos
AU - Lubman, Dan I.
AU - Meyerhoff, Dieter J.
AU - Ralph, Annaketurah
AU - Rezapour, Tara
AU - Tavakoli, Hosna
AU - Zare-Bidoky, Mehran
AU - Zilverstand, Anna
AU - Steele, Douglas
AU - Moeller, Scott J.
AU - Paulus, Martin P.
AU - Baldacchino, Alex
AU - Ekhtiari, Hamed
N1 - AV-G is supported by Australian Medical Research Future Fund Fellowship (MRF1141214). DM is supported by NIH R01DA039903. MB receives support from NIH R01AA023667. DLP is supported by the Office of Research and Development, Clinical Science Research and Development (CSR&D), Department of Veterans Affairs, Career Development Award—2 (1IK2CX001510-01). SJM was supported by NIH K01DA037452.
PY - 2019/12/23
Y1 - 2019/12/23
N2 - Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.
AB - Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAMNIG) to promote initiatives to bridge this gap. This article summarises the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools forthe assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualised prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioural outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design interventions based on multilevel targets, additional evidence from randomised trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonised protocols and data management systems, and prioritising multi-site research that focuses on improving clinical outcomes.
KW - Neuroscience
KW - Addiction Medicine
KW - Treatment
KW - Substance Use Disorder
KW - fMRI
KW - Neuromodulation
KW - Cognition
KW - Neuropsychological Assessment
KW - Cognitive Remediation
KW - Cognitive Training
U2 - 10.3389/fpsyt.2019.00877
DO - 10.3389/fpsyt.2019.00877
M3 - Article
C2 - 31920740
SN - 1664-0640
VL - 10
SP - 1
EP - 23
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 877
ER -